Gabriele Buchel
Overview
Explore the profile of Gabriele Buchel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
245
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grunewald L, Andersch L, Helmsauer K, Schwiebert S, Klaus A, Henssen A, et al.
Pharmacol Res
. 2025 Jan;
212:107608.
PMID: 39828101
Current treatment protocols have limited success against MYCN-amplified neuroblastoma. Adoptive T cell therapy presents an innovative strategy to improve cure rates. However, L1CAM-targeting CAR T cells achieved only limited response...
2.
Vidal R, Leen E, Herold S, Muller M, Fleischhauer D, Schulein-Volk C, et al.
Elife
. 2024 Aug;
13.
PMID: 39177021
MYC family oncoproteins regulate the expression of a large number of genes and broadly stimulate elongation by RNA polymerase II (RNAPII). While the factors that control the chromatin association of...
3.
Papadopoulos D, Ha S, Fleischhauer D, Uhl L, Russell T, Mikicic I, et al.
Mol Cell
. 2024 May;
84(11):2070-2086.e20.
PMID: 38703770
The MYCN oncoprotein binds active promoters in a heterodimer with its partner protein MAX. MYCN also interacts with the nuclear exosome, a 3'-5' exoribonuclease complex, suggesting a function in RNA...
4.
Alborzinia H, Chen Z, Yildiz U, Porto Freitas F, Vogel F, Varga J, et al.
EMBO Mol Med
. 2023 Jul;
15(8):e18014.
PMID: 37435859
Ferroptosis has emerged as an attractive strategy in cancer therapy. Understanding the operational networks regulating ferroptosis may unravel vulnerabilities that could be harnessed for therapeutic benefit. Using CRISPR-activation screens in...
5.
Roeschert I, Poon E, Henssen A, Dorado Garcia H, Gatti M, Giansanti C, et al.
Nat Cancer
. 2021 Mar;
2(3):312-326.
PMID: 33768209
Amplification of is the driving oncogene in a subset of high-risk neuroblastoma. The MYCN protein and the Aurora-A kinase form a complex during S phase that stabilizes MYCN. Here we...
6.
Wolpaw A, Bayliss R, Buchel G, Dang C, Eilers M, Gustafson W, et al.
Cancer Res
. 2021 Jan;
81(7):1627-1632.
PMID: 33509943
Effective treatment of pediatric solid tumors has been hampered by the predominance of currently "undruggable" driver transcription factors. Improving outcomes while decreasing the toxicity of treatment necessitates the development of...
7.
Herold S, Kalb J, Buchel G, Ade C, Baluapuri A, Xu J, et al.
Nature
. 2019 Mar;
567(7749):545-549.
PMID: 30894746
MYC is an oncogenic transcription factor that binds globally to active promoters and promotes transcriptional elongation by RNA polymerase II (RNAPII). Deregulated expression of the paralogous protein MYCN drives the...
8.
Batzke K, Buchel G, Hansen W, Schramm A
Int J Mol Sci
. 2018 Mar;
19(3).
PMID: 29498681
Galectin-1 (Gal-1) has been described to promote tumour growth by inducing angiogenesis and to contribute to the tumour immune escape. We had previously identified up-regulation of Gal-1 in preclinical models...
9.
Buchel G, Carstensen A, Mak K, Roeschert I, Leen E, Sumara O, et al.
Cell Rep
. 2017 Dec;
21(12):3483-3497.
PMID: 29262328
MYC proteins bind globally to active promoters and promote transcriptional elongation by RNA polymerase II (Pol II). To identify effector proteins that mediate this function, we performed mass spectrometry on...
10.
Buchel G, Schulte J, Harrison L, Batzke K, Schuller U, Hansen W, et al.
Oncoimmunology
. 2016 Jul;
5(5):e1131378.
PMID: 27467948
Galectin-1 (Gal-1) has been described to promote tumor growth by inducing angiogenesis and to contribute to tumor immune escape by promoting apoptosis of activated T cells. We had previously identified...